A COST-EFFECTIVENESS MODEL OF BAZEDOXIFENE VS. RALOXIFENE FOR THE PREVENTION OF FRACTURES IN SPANISH POSTMENOPAUSAL WOMEN

被引：0
|
作者：
Darba, Josep [1 ]
Perez-Alvarez, Nuria [2 ]
Kaskens, Lisette [2 ]
Racketa, Jill [3 ]
Rejas, Javier [4 ]
机构：
[1] Univ Barcelona, E-08007 Barcelona, Spain
[2] BCN Hlth Econ & Outcomes Res, Barcelona, Spain
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Hlth Econ & Outcomes Res Dept, Madrid, Spain
来源：
OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256 / 257
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of raloxifene and hormone replacement therapy in postmenopausal women.
    Chen, TM
    Armstrong, K
    Albert, D
    Hrung, J
    Schwartz, JS
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S45 - S45
  • [22] Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women
    Ellis, Alexandra G.
    Reginster, Jean-Yves
    Luo, Xuemei
    Bushmakin, Andrew G.
    Williams, Robert
    Sutradhar, Santosh
    Mirkin, Sebastian
    Jansen, Jeroen P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1617 - 1626
  • [23] Cost-effectiveness of teriparatide (Forteo) in the prevention of osteoporotic fractures among men and postmenopausal women in Australia
    Graham-Clarke, PL
    Lees, M
    Wolthers, T
    Thiebaud, D
    Price, N
    VALUE IN HEALTH, 2004, 7 (03) : 297 - 297
  • [24] Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women Response
    Tanaka, Shiro
    Kuroda, Tatsuhiko
    Sugimoto, Toshitsugu
    Nakamura, Toshitaka
    Shiraki, Masataka
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1627 - 1628
  • [25] Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women
    Christensen, PM
    Brixen, K
    Gyrd-Hansen, D
    Kristiansen, IS
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (05) : 387 - 396
  • [26] Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: Impact of breast cancer risk
    Armstrong, K
    Chen, TM
    Albert, D
    Randall, RC
    Schwartz, JS
    OBSTETRICS AND GYNECOLOGY, 2001, 98 (06): : 996 - 1003
  • [27] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS ALENDRONATE MONOTHERAPY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Williams, S.
    Fitzpatrick, L.
    Silverman, S.
    Weiss, R. J.
    Reginster, J. Y.
    VALUE IN HEALTH, 2019, 22 : S243 - S243
  • [28] Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
    Chen, Mingsheng
    Si, Lei
    Winzenberg, Tania M.
    Gu, Jieruo
    Jiang, Qicheng
    Palmer, Andrew J.
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 415 - 423
  • [29] COST-EFFECTIVENESS OF MYOMECTOMY VS. HYSTERECTOMY IN WOMEN WITH UTERINE FIBRIODS
    Thao, V
    Moriarty, J. P.
    Stewart, E. A.
    Borah, B.
    VALUE IN HEALTH, 2021, 24 : S101 - S101
  • [30] Cost-effectiveness of raloxifene for prevention of breast cancer in women treated with radiation for Hodgkin disease
    Allen, M. W.
    Perkins, G. H.
    Cantort, S. B.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (06): : 670 - 671
12345